PeptideStack
5.2kquestions
20kanswers
220users

Is a 99.1% result from Medutest comparable to 95.2% from PeptideMeter?

Asked 26 Jan 2025Modified 14 months agoViewed 13k times
22

Stated plainly: 99.1% · Medutest · 95.2% · PeptideMeter.

Both of these get recommended confidently by different people, which suggests neither is obviously right.

My constraints are cost, measurement resolution and how much handling I am prepared to do — in roughly that order.

What is the actual trade-off, and does it matter at the scale I am working at?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
reference-standard
reference-standard

Certified reference materials and in-house standards: traceability, the certificate of the standard itself, system suitability, and why every…

179 questions
shareeditfollowflag
EL
askedesben_lykke15k2826 Jan 2025
For what it is worth, my own result was within half a per cent of this. – mira_sundqvist 4 months ago
Any reason this would differ for a longer peptide? – halvard_ness 5 months ago
add a comment

4 Answers

Accepted answer first, then by votes
57

Accepted answer

Understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.

Compare purity within a single laboratory on the same method, never across laboratories.

edited 18 Feb 2025 by tobias_maartens — added the method parameters

shareimprove this answerflag
TM
answered · acceptedtobias_maartens94k25813 Feb 2025
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
38

Worth being precise here: the short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.

Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
BC
answeredbea_castellanos47k13822 May 2025
6Have you seen anything published on this, or is it inference from the mechanism? – e_dziedzic 5 months ago
5Useful. I have added the accept threshold suggestion to my own notes. – Dr_Jonas_Halvorsen 3 months ago
add a comment
26

The relevant detail is that the method matters more than the vial, which is why specifying a method buys you far more than changing suppliers does.

Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.

The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."

If you are ranking vendors, specify a method and have all samples tested at the same place.

edited 20 Mar 2025 by fill_volume — reworded for clarity after a comment

shareimprove this answerflag
FV
answeredfill_volume13k1824 Feb 2025
24

Worth being precise here: reporting threshold is convention and not chemistry, which is why two certificates with different thresholds disagree by a tenth of a point or more.

Integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
DA
answeredDr_Rosalind_Achebe90k1582 Feb 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.